Glyscend Therapeutics is a venture-backed, clinical-stage biopharmaceutical company developing oral, first-in-class therapies for type 2 diabetes and obesity.
The company evolved from the founding team’s research on how certain types of bariatric surgeries lead to significant improvements in glucose and metabolic regulation as well as sustained weight loss.
Using our Mucus Complexing Polymer (MCP) platform invented through research originating at Johns Hopkins University, Glyscend is targeting mechanisms inside the GI tract to treat a variety of metabolic and chronic conditions. In addition, the company is exploring program opportunities that address topical GI as well as GI-mediated systemic metabolic, inflammatory, and autoimmune conditions.
The team’s combined experience in gastroenterology, metabolism, polymer chemistry, and drug development is key to advancing a new generation of polymer therapies for treating T2D and obesity with the goal of improving patient outcomes and reducing costs across the healthcare system.
